Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Gains from Investment Securities (2023 - 2025)

Metagenomi (MGX) has disclosed Gains from Investment Securities for 3 consecutive years, with $343075.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 436.56% to $343075.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $343075.0, a 436.56% increase, with the full-year FY2025 number at -$2.2 million, down 3600.16% from a year prior.
  • Gains from Investment Securities was $343075.0 for Q3 2025 at Metagenomi, roughly flat from $343075.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $30.6 million in Q1 2023 to a low of $63940.0 in Q1 2024.
  • A 3-year average of $3.8 million and a median of $108089.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 99.79% in 2024, then surged 436.56% in 2025.
  • Metagenomi's Gains from Investment Securities stood at $2.3 million in 2023, then plummeted by 97.18% to $63940.0 in 2024, then soared by 436.56% to $343075.0 in 2025.
  • Per Business Quant, the three most recent readings for MGX's Gains from Investment Securities are $343075.0 (Q3 2025), $343075.0 (Q2 2025), and $108089.0 (Q1 2025).